scholarly journals Increased Human Growth Hormone After Oral Consumption of an Amino Acid Supplement

2019 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Charmaine S. Tam ◽  
William D. Johnson ◽  
Jennifer Rood ◽  
Amy L. Heaton ◽  
Frank L. Greenway
Diabetes ◽  
1980 ◽  
Vol 29 (10) ◽  
pp. 782-787 ◽  
Author(s):  
F. M. Ng ◽  
J. Bornstein ◽  
C. E. Pullin ◽  
J. O. Bromley ◽  
S. L. Macaulay

1984 ◽  
Vol 247 (5) ◽  
pp. E639-E644
Author(s):  
C. M. Cameron ◽  
J. L. Kostyo ◽  
J. A. Rillema ◽  
S. E. Gennick

The biological activity profile of reduced and S-carboxymethylated human growth hormone (RCM-hGH) was determined to establish its suitability for study of the diabetogenic property of hGH. RCM-hGH was found to have greatly attenuated in vivo growth-promoting activity in the 9-day weight-gain test in hypophysectomized rats (approximately 1%) and to have a similar low order of in vitro activity in stimulating amino acid incorporation into the protein of the isolated rat diaphragm. RCM-hGH also only had approximately 1% of the in vitro insulin-like activity of the native hormone on isolated adipose tissue from hypophysectomized rats. In contrast, RCM-hGH retained substantial in vivo diabetogenic activity in the ob/ob mouse, appearing to have approximately 50% of the activity of the native hormone. RCM-hGH was also found to retain significant, although attenuated (25%), in vitro lactogenic activity when tested for the ability to stimulate amino acid incorporation into a casein-rich protein fraction in mouse mammary gland explants. Because RCM-hGH exhibits a high degree of diabetogenic activity, although lacking significant anabolic or insulin-like activities, it will be useful as a "monovalent" probe for the study of the molecular mechanism of the diabetogenic action of GH.


2021 ◽  
Author(s):  
Andrei Rajkovic ◽  
Sandesh Kanchugal ◽  
Eldar Abdurakhmanov ◽  
Rebecca Howard ◽  
Astrid Gräslund ◽  
...  

The interaction between human Growth Hormone (hGH) and hGH Receptor (hGHR) has great relevance to human diseases such as acromegaly and cancer. HGH has been extensively engineered by other workers to improve binding and other properties. We used a computational screen to select substitutions at single hGH positions within the hGHR-binding site. We find that, while many successfully slow down dissociation of the hGH-hGHR complex once bound, they also slow down the association of hGH to hGHR. We are particularly interested in E174 which belongs to the hGH zinc-binding triad, and which spans coiled-coil helices and obeys the coiled-coil heptad pattern. Surprisingly, substituting E174 with A leads to substantial increase in an experimental measure of coiled-coil content. E174A is known to increase affinity of hGH against hGHR; here we show that this is simply because the off-rate is slowed down more than the on-rate, in line with what has been found for other affinity-improving mutations. For E174Y (and mutations at other sites) the slowdown in on-rate was greater, leading to decreased affinity. The results point to a link between coiled-coiling, zinc binding, and hGHR-binding affinity in hGH, and also suggest rules for choosing affinity-increasing substitutions.


2021 ◽  
Vol 478 (19) ◽  
pp. 3527-3537
Author(s):  
Nicole K. Thompson ◽  
Leif T. N. LeClaire ◽  
Samantha Rodriguez Perez ◽  
Warren W. Wakarchuk

We have been developing bacterial expression systems for human mucin-type O-glycosylation on therapeutic proteins, which is initiated by the addition of α-linked GalNAc to serine or threonine residues by enzymes in the GT-27 family of glycosyltransferases. Substrate preference across different isoforms of this enzyme is influenced by isoform-specific amino acid sequences at the site of glycosylation, which we have exploited to engineer production of Core 1 glycan structures in bacteria on human therapeutic proteins. Using RP-HPLC with a novel phenyl bonded phase to resolve intact protein glycoforms, the effect of sequon mutation on O-glycosylation initiation was examined through in vitro modification of the naturally O-glycosylated human interferon α-2b, and a sequon engineered human growth hormone. As part of the development of our glycan engineering in the bacterial expression system we are surveying various orthologues of critical enzymes to ensure complete glycosylation. Here we present an in vitro enzyme kinetic profile of three related GT-27 orthologues on natural and engineered sequons in recombinant human interferon α2b and human growth hormone where we show a significant change in kinetic properties with the amino acid changes. It was found that optimizing the protein substrate amino acid sequence using Isoform Specific O-Glycosylation Prediction (ISOGlyP, http://isoglyp.utep.edu/index.php) resulted in a measurable increase in kcat/KM, thus improving glycosylation efficiency. We showed that the Drosophila orthologue showed superior activity with our human growth hormone designed sequons compared with the human enzyme.


PROTEOMICS ◽  
2006 ◽  
Vol 6 (3) ◽  
pp. 775-784 ◽  
Author(s):  
Felix Hepner ◽  
Edina Csaszar ◽  
Elisabeth Roitinger ◽  
Arnold Pollak ◽  
Gert Lubec

1995 ◽  
Vol 44 (6) ◽  
pp. 265-267 ◽  
Author(s):  
A. Szabó ◽  
E. Kenesei ◽  
T. Tulassay ◽  
P. Sallay ◽  
L. Szücs ◽  
...  

1993 ◽  
Vol 3 (3) ◽  
pp. 290-297 ◽  
Author(s):  
G. Mikael Fogelholm ◽  
Hannu K. Näveri ◽  
Kai T.K. Kiilavuori ◽  
Matti H.A. HärkÖnen

Using a double-blind, crossover protocol, we studied the possible effects of a 4-day combined L-arginine, L-ornithine, and L-lysine supplementation (each 2 g/day, divided into two daily doses) on 24-hr level of serum human growth hormone (hGH) and insulin in 11 competitive weightlifters, ages 19 to 35 yrs. Three similar daily hGH peaks, seemingly preceded by a decrease in serum insulin concentration, were found during both amino acid and placebo supplementation. Supplementation did not affect the physiological variation of serum hGH concentration (treatment and treatment × time interaction:p=0.43–0.55). Analogously, serum insulin levels were not higher after amino acid supplementation. Therefore the ergogenic value of lowdose oral amino acid supplementation in increasing hGH or insulin secretion seems questionable.


1983 ◽  
Vol 2 (4) ◽  
pp. 341-346
Author(s):  
Willard P. VanderLaan ◽  
Nicholas Ling ◽  
Eileen F. VanderLaan ◽  
Morton B. Sigel ◽  
Urban J. Lewis

1985 ◽  
Vol 19 (4) ◽  
pp. 188A-188A
Author(s):  
Wendy J Maury ◽  
Alan P Rogol ◽  
Thaddeus E Kelly ◽  
Christopher Y Thomas

Sign in / Sign up

Export Citation Format

Share Document